利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.036 秒)

    QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES
    2.
    发明申请
    QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES 有权
    喹诺酮羧酸取代的赖氨明衍生物

    公开(公告)号：US20090143373A1

    公开(公告)日：2009-06-04

    申请号：US12269652

    申请日：2008-11-12

    申请人： Charles Z. Ding ,  Yafei Jin ,  Keith Combrink ,  In Ho Kim

    发明人： Charles Z. Ding ,  Yafei Jin ,  Keith Combrink ,  In Ho Kim

    IPC分类号： A61K31/4709 ,  C07D498/04 ,  C07D471/20 ,  A61K31/5383 ,  A61P31/04

    CPC分类号： C07D491/20 ,  C07D498/16

    摘要： The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the inventive compounds is that both the rifamycin and quinolone antibacterial pharmacophores are co-delivered with matched pharmacokinetics to the targeted pathogens of interests. Delivery of multiple antibacterial pharmacophores simultaneously to the targeted pathogens has the maximum chance of achieving synergy and minimizing the development of resistance to the antibiotics given.

    摘要翻译： 化合物包括取代的利福霉素衍生物，其中喹诺酮羧酸药效团与苯并恶嗪利福霉素或螺哌啶利多霉素共价键合。 利福霉素衍生物可用作抗微生物剂，并且对许多人和兽医革兰氏阳性和革兰氏阴性病原体有效。 本发明化合物的优点在于利福霉素和喹诺酮类抗菌药代动力剂与匹配的药代动力学共同输送到感兴趣的靶向病原体。 同时向目标病原体递送多个抗菌药代动力，最大限度地实现协同作用，并最大限度地减少给予抗生素的耐药性。

    Quinolone carboxylic acid-substituted rifamycin derivatives
    3.
    发明授权
    Quinolone carboxylic acid-substituted rifamycin derivatives 有权
    喹诺酮羧酸取代的利福霉素衍生物

    公开(公告)号：US07884099B2

    公开(公告)日：2011-02-08

    申请号：US12269652

    申请日：2008-11-12

    申请人： Charles Z. Ding ,  Yafei Jin ,  Keith Combrink ,  In Ho Kim

    发明人： Charles Z. Ding ,  Yafei Jin ,  Keith Combrink ,  In Ho Kim

    IPC分类号： C07D491/20 ,  C07D498/16 ,  A61K31/498 ,  A61K31/5383

    CPC分类号： C07D491/20 ,  C07D498/16

    摘要： The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the inventive compounds is that both the rifamycin and quinolone antibacterial pharmacophores are co-delivered with matched pharmacokinetics to the targeted pathogens of interests. Delivery of multiple antibacterial pharmacophores simultaneously to the targeted pathogens has the maximum chance of achieving synergy and minimizing the development of resistance to the antibiotics given.

    摘要翻译： 化合物包括取代的利福霉素衍生物，其中喹诺酮羧酸药效团与苯并恶嗪利福霉素或螺哌啶利多霉素共价键合。 利福霉素衍生物可用作抗微生物剂，并且对许多人和兽医革兰氏阳性和革兰氏阴性病原体有效。 本发明化合物的优点在于利福霉素和喹诺酮类抗菌药代动力剂与匹配的药代动力学共同输送到感兴趣的靶向病原体。 同时向目标病原体递送多个抗菌药代动力，最大限度地实现协同作用，并最大限度地减少给予抗生素的耐药性。

    Rifamycin imino derivatives effective against drug-resistant microbes
    4.
    发明授权
    Rifamycin imino derivatives effective against drug-resistant microbes 有权
    对抗耐药性微生物有效的利福霉素亚氨基衍生物

    公开(公告)号：US07238694B2

    公开(公告)日：2007-07-03

    申请号：US11034279

    申请日：2005-01-12

    申请人： Charles Z. Ding ,  Yafei Jin ,  Jamie C. Longgood ,  Zhenkun Ma ,  Jing Li ,  In Ho Kim ,  Keith P. Minor ,  Susan Harran

    发明人： Charles Z. Ding ,  Yafei Jin ,  Jamie C. Longgood ,  Zhenkun Ma ,  Jing Li ,  In Ho Kim ,  Keith P. Minor ,  Susan Harran

    IPC分类号： C07D498/08 ,  C07D519/00 ,  A61K31/4709 ,  A61K31/496 ,  A61P31/04

    CPC分类号： C07D498/08 ,  C07D519/00

    摘要： The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

    摘要翻译： 本发明涉及具有抗菌活性的利福霉素3-亚氨基亚甲基（-CH-N-）衍生物，其包括抗药性微生物的活性。 所要求的利福霉素衍生物具有通过利莫霉素部分的C-3碳上的亚氨基亚甲基（-CH-N-）基团与连接体共价连接的利福霉素部分，并且连接体又与喹诺酮结构共价连接或其 DNA促旋酶和拓扑异构酶IV抑制剂家族内的药效团。 本发明的利福霉素是新颖的，并且表现出抵抗利福平和环丙沙星抗性微生物的活性。

    Rifamycin derivatives
    8.
    发明授权
    Rifamycin derivatives 有权
    利福霉素衍生物

    公开(公告)号：US07229996B2

    公开(公告)日：2007-06-12

    申请号：US11186187

    申请日：2005-07-21

    申请人： Zhenkun Ma ,  Jing Li ,  Susan Harran ,  Yong He ,  Keith P. Minor ,  In Ho Kim ,  Charles Z. Ding ,  Jamie C. Longgood ,  Yafei Jin ,  Keith D. Combrink

    发明人： Zhenkun Ma ,  Jing Li ,  Susan Harran ,  Yong He ,  Keith P. Minor ,  In Ho Kim ,  Charles Z. Ding ,  Jamie C. Longgood ,  Yafei Jin ,  Keith D. Combrink

    IPC分类号： C07D498/08 ,  A61K31/4709 ,  A61P31/04

    CPC分类号： C07D401/12 ,  C07D455/02

    摘要： Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

    摘要翻译： 式I的新型利福霉素衍生物（氢醌和相应的醌（C 1 -C 4））形成）：或其盐，水合物或前药，其中：优选的R 包括氢，乙酰基; L是接头，优选的连接基团元素选自1至5个组的任何组合，如图1所示。 1，其中L不是其中R 1是H，甲基或烷基。 本发明化合物显示出有价值的抗生素性质。 具有这些化合物的制剂可以用于控制或预防哺乳动物，包括人和非人的感染性疾病。 特别地，这些化合物甚至显示出显着的抗菌活性，即使是针对多抗菌菌株的微生物。